secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0001493152-24-005043
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma prices $15M public offering of 5.5M shares at $2.71/share
-------------------------------------------------------------------------

- Offering of 5,535,055 shares at $2.71 per share; gross proceeds ~$15M before expenses.
- Underwriter granted 30-day over-allotment option for up to 783,970 additional shares.
- Net proceeds to fund NXC-201 clinical trials, working capital, and general corporate purposes.
- Closing expected February 8, 2024; subject to customary conditions.
- Directors and officers subject to 90-day lock-up expiring May 8, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315224005043/0001493152-24-005043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315224005043/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-005043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer